{"id":"https://openalex.org/W2468340320","doi":"https://doi.org/10.1021/acs.molpharmaceut.6b00315","title":"Reduced Crystallization Temperature Methodology for Polymer Selection in Amorphous Solid Dispersions: Stability Perspective","display_name":"Reduced Crystallization Temperature Methodology for Polymer Selection in Amorphous Solid Dispersions: Stability Perspective","publication_year":2016,"publication_date":"2016-07-14","ids":{"openalex":"https://openalex.org/W2468340320","doi":"https://doi.org/10.1021/acs.molpharmaceut.6b00315","mag":"2468340320","pmid":"https://pubmed.ncbi.nlm.nih.gov/27414755"},"language":"en","primary_location":{"id":"doi:10.1021/acs.molpharmaceut.6b00315","doi":"https://doi.org/10.1021/acs.molpharmaceut.6b00315","is_oa":false,"landing_page_url":"https://doi.org/10.1021/acs.molpharmaceut.6b00315","pdf_url":null,"source":{"id":"https://openalex.org/S204562082","display_name":"Molecular Pharmaceutics","issn_l":"1543-8384","issn":["1543-8384","1543-8392"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Pharmaceutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2468340320"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5004194673","display_name":"Chandan Bhugra","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210160255","display_name":"Boehringer Ingelheim (United States)","ror":"https://ror.org/05kffp613","country_code":"US","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210160255"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Chandan Bhugra","raw_affiliation_strings":["Pharmaceutical Development, Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut 06877, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Development, Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut 06877, United States","institution_ids":["https://openalex.org/I4210160255"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050540235","display_name":"Chitra Telang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210160255","display_name":"Boehringer Ingelheim (United States)","ror":"https://ror.org/05kffp613","country_code":"US","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210160255"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chitra Telang","raw_affiliation_strings":["Pharmaceutical Development, Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut 06877, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Development, Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut 06877, United States","institution_ids":["https://openalex.org/I4210160255"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045751410","display_name":"Robert J. Schwabe","orcid":"https://orcid.org/0000-0001-6732-7559","observed_orcids":["https://orcid.org/0000-0001-6732-7559"]},"institutions":[{"id":"https://openalex.org/I4210160255","display_name":"Boehringer Ingelheim (United States)","ror":"https://ror.org/05kffp613","country_code":"US","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210160255"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert Schwabe","raw_affiliation_strings":["Pharmaceutical Development, Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut 06877, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Development, Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut 06877, United States","institution_ids":["https://openalex.org/I4210160255"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5100664782","display_name":"Li Sheng Zhong","orcid":"https://orcid.org/0000-0003-1070-280X","observed_orcids":["https://orcid.org/0000-0003-1070-280X"]},"institutions":[{"id":"https://openalex.org/I4210160255","display_name":"Boehringer Ingelheim (United States)","ror":"https://ror.org/05kffp613","country_code":"US","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210160255"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Li Zhong","raw_affiliation_strings":["Pharmaceutical Development, Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut 06877, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Development, Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut 06877, United States","institution_ids":["https://openalex.org/I4210160255"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5004194673"],"corresponding_institution_ids":["https://openalex.org/I4210160255"],"apc_list":{"value":4500,"currency":"USD","value_usd":4500},"apc_paid":null,"fwci":0.8685,"has_fulltext":false,"cited_by_count":16,"citation_normalized_percentile":{"value":0.63504956,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"13","issue":"9","first_page":"3326","last_page":"3333"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10256","display_name":"Drug Solubulity and Delivery Systems","score":0.9901999831199646,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10256","display_name":"Drug Solubulity and Delivery Systems","score":0.9901999831199646,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11881","display_name":"Crystallization and Solubility Studies","score":0.005799999926239252,"subfield":{"id":"https://openalex.org/subfields/2505","display_name":"Materials Chemistry"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10920","display_name":"Advanced Drug Delivery Systems","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/amorphous-solid-dispersions","display_name":"amorphous solid dispersions","score":0.9739999771118164},{"id":"https://openalex.org/keywords/polymer-selection","display_name":"polymer selection","score":0.906000018119812},{"id":"https://openalex.org/keywords/physical-stability","display_name":"physical stability","score":0.7770000100135803},{"id":"https://openalex.org/keywords/crystallization-parameters","display_name":"crystallization parameters","score":0.8629999756813049},{"id":"https://openalex.org/keywords/nifedipine","display_name":"nifedipine","score":0.9909999966621399},{"id":"https://openalex.org/keywords/polymer-matrix","display_name":"polymer matrix","score":0.4790000021457672},{"id":"https://openalex.org/keywords/polyvinylpyrrolidone","display_name":"polyvinylpyrrolidone","score":0.4860000014305115},{"id":"https://openalex.org/keywords/soluplus","display_name":"Soluplus","score":0.9819999933242798},{"id":"https://openalex.org/keywords/hpmcas","display_name":"HPMCAS","score":0.9049999713897705},{"id":"https://openalex.org/keywords/polyvinyl-acetate","display_name":"polyvinyl acetate","score":0.6710000038146973},{"id":"https://openalex.org/keywords/paas","display_name":"PaaS","score":0.843999981880188},{"id":"https://openalex.org/keywords/drug-loading","display_name":"drug loading","score":0.4650000035762787},{"id":"https://openalex.org/keywords/supersaturation","display_name":"supersaturation","score":0.6039999723434448},{"id":"https://openalex.org/keywords/accelerated-stress-testing","display_name":"accelerated stress testing","score":0.5320000052452087}],"concepts":[{"id":"https://openalex.org/C203036418","wikidata":"https://www.wikidata.org/wiki/Q284256","display_name":"Crystallization","level":2,"score":0.7512127757072449},{"id":"https://openalex.org/C56052488","wikidata":"https://www.wikidata.org/wiki/Q103382","display_name":"Amorphous solid","level":2,"score":0.6558917760848999},{"id":"https://openalex.org/C12713177","wikidata":"https://www.wikidata.org/wiki/Q1900281","display_name":"Perspective (graphical)","level":2,"score":0.589841902256012},{"id":"https://openalex.org/C192562407","wikidata":"https://www.wikidata.org/wiki/Q228736","display_name":"Materials science","level":0,"score":0.5514904856681824},{"id":"https://openalex.org/C521977710","wikidata":"https://www.wikidata.org/wiki/Q81163","display_name":"Polymer","level":2,"score":0.4937842786312103},{"id":"https://openalex.org/C112972136","wikidata":"https://www.wikidata.org/wiki/Q7595718","display_name":"Stability (learning theory)","level":2,"score":0.4742937386035919},{"id":"https://openalex.org/C42360764","wikidata":"https://www.wikidata.org/wiki/Q83588","display_name":"Chemical engineering","level":1,"score":0.3740394711494446},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.27829837799072266},{"id":"https://openalex.org/C8010536","wikidata":"https://www.wikidata.org/wiki/Q160398","display_name":"Crystallography","level":1,"score":0.1844567060470581},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.18142801523208618},{"id":"https://openalex.org/C127413603","wikidata":"https://www.wikidata.org/wiki/Q11023","display_name":"Engineering","level":0,"score":0.13411083817481995},{"id":"https://openalex.org/C159985019","wikidata":"https://www.wikidata.org/wiki/Q181790","display_name":"Composite material","level":1,"score":0.11131510138511658},{"id":"https://openalex.org/C154945302","wikidata":"https://www.wikidata.org/wiki/Q11660","display_name":"Artificial intelligence","level":1,"score":0.10021209716796875},{"id":"https://openalex.org/C119857082","wikidata":"https://www.wikidata.org/wiki/Q2539","display_name":"Machine learning","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D003460","descriptor_name":"Crystallization","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004355","descriptor_name":"Drug Stability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009543","descriptor_name":"Nifedipine","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D011108","descriptor_name":"Polymers","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D011145","descriptor_name":"Polyvinyls","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D011759","descriptor_name":"Pyrrolidines","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D013696","descriptor_name":"Temperature","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D044366","descriptor_name":"Transition Temperature","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1021/acs.molpharmaceut.6b00315","doi":"https://doi.org/10.1021/acs.molpharmaceut.6b00315","is_oa":false,"landing_page_url":"https://doi.org/10.1021/acs.molpharmaceut.6b00315","pdf_url":null,"source":{"id":"https://openalex.org/S204562082","display_name":"Molecular Pharmaceutics","issn_l":"1543-8384","issn":["1543-8384","1543-8392"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Pharmaceutics","raw_type":"journal-article"},{"id":"pmid:27414755","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/27414755","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular pharmaceutics","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":20,"referenced_works":["https://openalex.org/W53851219","https://openalex.org/W205849754","https://openalex.org/W1970767638","https://openalex.org/W1998970318","https://openalex.org/W2029074560","https://openalex.org/W2033928617","https://openalex.org/W2036273612","https://openalex.org/W2039113085","https://openalex.org/W2046406092","https://openalex.org/W2054865296","https://openalex.org/W2056491432","https://openalex.org/W2057302487","https://openalex.org/W2069580393","https://openalex.org/W2078216448","https://openalex.org/W2079193883","https://openalex.org/W2083296816","https://openalex.org/W2084253981","https://openalex.org/W2087242525","https://openalex.org/W2143076068","https://openalex.org/W2312270785"],"related_works":["https://openalex.org/W2613516753","https://openalex.org/W2761098084","https://openalex.org/W2044146593","https://openalex.org/W2544584945","https://openalex.org/W3024736162","https://openalex.org/W2776208400","https://openalex.org/W2742631421","https://openalex.org/W4290974105","https://openalex.org/W2765586046","https://openalex.org/W1974777977"],"abstract_inverted_index":{"API-polymer":[0,119],"interactions,":[1],"used":[2],"to":[3,12,36,90,96,143,184,264],"select":[4],"the":[5,124,238],"right":[6],"polymeric":[7],"matrix":[8],"with":[9],"an":[10,14],"aim":[11],"stabilize":[13],"amorphous":[15,44],"dispersion,":[16],"are":[17],"routinely":[18],"studied":[19],"using":[20],"spectroscopic":[21],"and/or":[22],"calorimetric":[23],"techniques":[24],"(i.e.,":[25],"melting":[26],"point":[27],"depression).":[28],"An":[29],"alternate":[30],"selection":[31],"tool":[32],"has":[33],"been":[34],"explored":[35],"rank":[37,71,111,139,156],"order":[38,112,125],"polymers":[39,221],"for":[40,50,70,102,121,152,160,175,203],"formation":[41],"of":[42,56,88,113,118,146,225,241],"stable":[43,202],"dispersions":[45,192],"as":[46,180,209,211,245],"a":[47,58,116],"pragmatic":[48],"method":[49],"polymer":[51,85,92,246],"selection.":[52],"Reduced":[53],"crystallization":[54,81],"temperature":[55,82],"API,":[57],"parameter":[59],"introduced":[60],"by":[61],"Zhou":[62],"et":[63],"al.,1":[64],"was":[65,141,158],"utilized":[66,95],"in":[67,74,79,248],"this":[68],"study":[69],"ordering":[72,140,157],"interactions":[73,148],"API-polymeric":[75],"systems.":[76],"The":[77,110],"trends":[78],"reduced":[80],"monitored":[83],"over":[84],"concentration":[86],"range":[87],"up":[89],"20%":[91],"loading":[93],"were":[94,178,200],"calculate":[97],"\"crystallization":[98],"parameter\"":[99],"or":[100],"CP":[101,188,218],"two":[103],"model":[104],"systems":[105],"(nifedipine":[106],"and":[107,149,198,253,255],"BI":[108,161,176,190,271],"ABC).":[109],"CP,":[114],"i.e.,":[115],"measure":[117],"interaction,":[120],"nifedipine":[122,185],"followed":[123],"PVP":[126,165],">":[127,129,131,133,136,164,166,168,170,172],"PVP-VA":[128],"Soluplus":[130,169],"HPMCAS":[132,167],"PV":[134],"Ac":[135],"PAA.":[137],"This":[138],"correlated":[142],"published":[144],"results":[145],"molecular":[147],"physical":[150],"stability":[151,226,229,265],"nifedipine.":[153],"A":[154],"different":[155],"observed":[159],"ABC:":[162],"PAA":[163],"PVPV-VA":[171],"PVAc.":[173],"Interactions":[174],"ABC":[177,191],"not":[179],"differentiated":[181],"when":[182],"compared":[183,263],"based":[186],"on":[187],"trends.":[189],"at":[193,230],"drug":[194,233],"loadings":[195,234],"between":[196],"40":[197],"60%":[199],"physically":[201],"prolonged":[204],"periods":[205],"under":[206],"ICH":[207],"conditions":[208],"well":[210],"accelerated":[212],"stress.":[213],"We":[214],"propose":[215],"that":[216,237],"large":[217],"differences":[219],"among":[220],"could":[222],"be":[223,261],"predictive":[224],"outcomes.":[227],"Acceptable":[228],"pharmaceutically":[231],"relevant":[232],"would":[235],"suggest":[236],"relative":[239],"influence":[240],"downstream":[242],"processes,":[243],"such":[244],"solubility":[247],"various":[249],"solvents,":[250],"process":[251],"suitability":[252],"selection,":[254],"more":[256],"importantly":[257],"supersaturation":[258],"potential,":[259],"should":[260],"higher":[262],"considerations":[266],"while":[267],"developing":[268],"compounds":[269],"like":[270],"ABC.":[272]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-07-22T00:00:00"}
